Journal
CURRENT GENE THERAPY
Volume 20, Issue 1, Pages 64-70Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1566523220666200309125709
Keywords
REIC/Dkk-3; gene therapy; apoptosis; biliary cancer; chemotherapy; cisplatin
Categories
Funding
- JSPS KAKENHI [17K15946]
- Grants-in-Aid for Scientific Research [17K15946] Funding Source: KAKEN
Ask authors/readers for more resources
Background: We previously demonstrated that the reduced expression in immortalized cells (REIC)/dikkopf-3 (Dkk-3) gene was downregulated in various malignant tumors, and that an adenovirus vector carrying the REIC/Dkk-3 gene, termed Ad-REIC induced cancer-selective apoptosis in pancreatic cancer and hepatocellular carcinoma. Objective: In this study, we examined the therapeutic effects of Ad-REIC in biliary cancer using a second-generation Ad-REIC (Ad-SGE-REIC). Methods: Human biliary cancer cell lines (G-415, TFK-1) were used in this study. The cell viability and apoptotic effect of Ad-SGE-REIC were assessed in vitro using an MTT assay and Hoechst staining. The anti-tumor effect in vivo was assessed in a mouse xenograft model. We also assessed the therapeutic effects of Ad-SGE-REIC therapy with cisplatin. Cell signaling was assessed by Western blotting. Results: Ad-SGE-REIC reduced cell viability, and induced apoptosis in biliary cancer cell lines via the activation of the c-Jun N-terminal kinase pathway. Ad-SGE-REIC also inhibited tumor growth in a mouse xenograft model. This effect was further enhanced in combination with cisplatin. Conclusion: Ad-SGE-REIC induced apoptosis and inhibited tumor growth in biliary cancer cells. REIC/Dkk-3 gene therapy using Ad-SGE-REIC is an attractive therapeutic tool for biliary cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available